LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

A number of analysts recently issued reports on the company. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice ...

In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day AUTL -4.72% DJIA -0.16% Russell 2K 0.15% Health Care/Life Sciences 0.69% ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces ...

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies ...